Synageva Biopharma Corp (GEVA) 238.60 $GEVA
Alacrita Appoints Markus Peters to Advise Clients on the Global Commercialization of Early and Late Stage Biopharmaceutical Assets
PR Newswire - Fri Jan 08, 7:00AM CST
Alacrita, the life sciences consulting firm, today announced that it has appointed Markus Peters, PhD, as Associate Partner in its Cambridge, MA office to advise clients on the global commercialization of early and late stage biopharmaceutical assets.
GEVA: 238.60 (+2.80)
CANbridge Appoints Mark A. Goldberg as Acting Chief Medical Officer
BusinessWire - Tue Oct 20, 7:02AM CDT
CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has appointed Mark A. Goldberg, MD, as Acting Chief Medical Officer (CMO), to take effect immediately.
GEVA: 238.60 (+2.80), IDRA: 1.64 (-0.04)
This Drugmaker's Incredible Run Looks Far From Done
Brian Feroldi, The Motley Fool - Motley Fool - Wed Aug 19, 7:16AM CDT
Photo by Images of Money / Flickr creative commons. "I missed it." I can't tell you how many times I've uttered those words to myself after I look at the long-term chart of a winning stock. When a stock has been a rocket ship over the past one,...
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 89.65 (-1.84), SRPT: 22.42 (-0.20), FOLD: 6.00 (unch)
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2015
M2 - Mon Jun 29, 9:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jfsvdb/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - ArmaGen Technologies, Inc. - Axcentua Pharmaceuticals AB - BioMarin Pharmaceutical Inc. - Dorphan S.A. - Laboratorios Del Dr. Esteve S.A. - Shire Plc - Synageva BioPharma Corp. - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/jf...saccharido
GEVA: 238.60 (+2.80), BMRN: 89.65 (-1.84), SHPG: 187.47 (-0.74)
5 Healthy Stocks in the Top Biotech ETF - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jun 17, 2:30AM CDT
We have highlighted the five best performing stocks in the top biotech ETF that more than doubled so far this year.
SBIO: 23.85 (+0.23), HALO: 9.17 (+0.06), GEVA: 238.60 (+2.80), IMGN: 3.08 (-0.12), HZNP: 19.15 (+0.44), ANAC: 99.06 (-0.14)
Lysosomal Storage Disorder Pipeline Review, H1 2015 - 15 Companies & 27 Drug Profiles
M2 - Thu Jun 11, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxz52s/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - BBB Therapeutics B.V. - Chiesi Farmaceutici SpA - Fate Therapeutics, Inc. - Minoryx Therapeutics s.l. - Neuralstem, Inc. - Nuo Therapeutics, Inc. - Orphazyme ApS - Oxyrane Belgium NV - REGiMMUNE Corporation - Sagetis Biotech, S.L. - Sangamo BioSciences, Inc. - Synageva BioPharma Corp. - Ultragenyx Pharmaceutical Inc. Drug Profiles - 2B3-201 - ALD-601 - Chaperone-ERT Combinations - Delta-tocopherol - FT-1050 - ML-SA1 - NSI-566 - Orph-001 - Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Recombinant Enzyme for LSD-2 Disease - Recombinant Enzyme for LSD-3 Disease - Recombinant Enzyme for LSD-4 Disease - Recombinant Enzyme for LSD-5 Disease - Recombinant Enzyme for Lysosomal Storage Disorder - Recombinant Enzyme to Activate LRP1 for Lysosomal Storage Disorder - RGI-5000 - SAG-002 - SBLSD-3 - SBLSD-4 - sebelipase alfa - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecules for GM1-gangliosidosis And Morquio B - Small Molecules for Lysosomal Storage Disorders - Stem Cell Therapy for Lysosomal Storage Disorder - UX-002 - UX-004 - ZA-011 For more information visit http://www.researchandmarkets.com/research/vx...al_storage
FATE: 1.73 (-0.04), GEVA: 238.60 (+2.80), SGMO: 6.09 (-0.09), FOLD: 6.00 (unch), CUR: 0.29 (unch)
Synageva BioPharma Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB
PR Newswire - Thu Jun 04, 3:05PM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the completion of enrollment in a Phase 1/2 trial with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome).
GEVA: 238.60 (+2.80)
Fabry Disease Pipeline Review, H1 2015 Edition
M2 - Thu Jun 04, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9l8prv/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - Synageva BioPharma Corp. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Alpha-Galactosidase - Genz-682452 - GZ-402671 - JR-051 - migalastat hydrochloride - Next Generation biologics for Pompe, Fabry and Hunter - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease For more information visit http://www.researchandmarkets.com/research/9l...ry_disease
GEVA: 238.60 (+2.80), IBIO: 0.69 (+0.01), FOLD: 6.00 (unch)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Synageva BioPharma Corp.
BusinessWire - Tue Jun 02, 6:29PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp. ("Synageva" or "the Company"
(Nasdaq: GEVA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion" .
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
Alexion satisfies Hart-Scott-Rodino waiting period for proposed acquisition of Synageva
M2 - Mon Jun 01, 3:24AM CDT
Biopharmaceutical company Alexion Pharmaceuticals (Nasdaq:ALXN) said on Friday that it has met the US Federal Trade Commission's (FTC) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to its planned acquisition of Synageva BioPharma (Nasdaq:GEVA).
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion's Pending Acquisition of Synageva
BusinessWire - Fri May 29, 3:20PM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Synageva BioPharma Corp. (Nasdaq:GEVA) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Alexion's pending acquisition of Synageva. The waiting period was scheduled to expire on June 15, 2015.
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
Synageva BioPharma Files for Kanuma's Approval in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 27, 11:30AM CDT
Synageva BioPharma Corp. (GEVA) submitted its New Drug Application (NDA) for Kanuma (sebelipase alfa) in Japan for the treatment for patients suffering from lysosomal acid lipase deficiency.
VRX: 23.29 (+0.04), GEVA: 238.60 (+2.80), GILD: 86.85 (+0.30), ALXN: 125.47 (+1.05)
Synageva BioPharma Submits Kanuma(TM) (Sebelipase Alfa) Application For LAL Deficiency In Japan
PR Newswire - Tue May 26, 3:05PM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kanuma(TM) (sebelipase alfa) as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency). Upon approval, Kanuma would be the first approved therapy for these patients.
GEVA: 238.60 (+2.80)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Synageva BioPharma Corp. -GEVA
PR Newswire - Fri May 22, 10:26AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp. ("Synageva" or "the Company" (Nasdaq -GEVA-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion" .
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synageva BioPharma Corp. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Alexion Pharmaceuticals, Inc. -- GEVA
PR Newswire - Mon May 18, 3:10PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
SYNAGEVA BIOPHARMA CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Synageva BioPharma Corp. Over the Proposed Sale of the Company to Alexion Pharmaceuticals, Inc.
BusinessWire - Mon May 18, 1:28PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synageva BioPharma, Inc. ("Synageva" or the "Company" (Nasdaq: GEVA) for potential breaches of fiduciary duties in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion" (Nasdaq: ALXN) for approximately $8.4 billion in a cash and stock transaction. The deal gives Synageva shares a total value of $226; $115 of which will be paid in cash, while the remaining $111 will be paid for in Alexion stock.
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva BioPharma Corp. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Wed May 13, 3:37PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synageva BioPharma Corp. ("Synageva" or the "Company" (Nasdaq: GEVA) relating to the proposed buyout of the Company by Alexion Pharmaceuticals, Inc.
GEVA: 238.60 (+2.80)
Alacrita Appoints Markus Peters to Advise Clients on the Global Commercialization of Early and Late Stage Biopharmaceutical Assets
PR Newswire - Fri Jan 08, 7:00AM CST
Alacrita, the life sciences consulting firm, today announced that it has appointed Markus Peters, PhD, as Associate Partner in its Cambridge, MA office to advise clients on the global commercialization of early and late stage biopharmaceutical assets.
GEVA: 238.60 (+2.80)
CANbridge Appoints Mark A. Goldberg as Acting Chief Medical Officer
BusinessWire - Tue Oct 20, 7:02AM CDT
CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has appointed Mark A. Goldberg, MD, as Acting Chief Medical Officer (CMO), to take effect immediately.
GEVA: 238.60 (+2.80), IDRA: 1.64 (-0.04)
This Drugmaker's Incredible Run Looks Far From Done
Brian Feroldi, The Motley Fool - Motley Fool - Wed Aug 19, 7:16AM CDT
Photo by Images of Money / Flickr creative commons. "I missed it." I can't tell you how many times I've uttered those words to myself after I look at the long-term chart of a winning stock. When a stock has been a rocket ship over the past one,...
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
Pompe Disease - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d3wrwn/pompe_disease) has announced the addition of the "Pompe Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pompe Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pompe Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Amicus Therapeutics, Inc. - Audentes Therapeutics, Inc. - BioMarin Pharmaceutical Inc. - Cortex Pharmaceuticals, Inc. - EpiVax, Inc. - Genzyme Corporation - Oxyrane Belgium NV - Pharming Group N.V. - Sarepta Therapeutics, Inc. - Synageva BioPharma Corp. For more information visit http://www.researchandmarkets.com/research/d3...pe_disease
GEVA: 238.60 (+2.80), BMRN: 89.65 (-1.84), SRPT: 22.42 (-0.20), FOLD: 6.00 (unch)
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2015
M2 - Mon Jun 29, 9:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jfsvdb/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - ArmaGen Technologies, Inc. - Axcentua Pharmaceuticals AB - BioMarin Pharmaceutical Inc. - Dorphan S.A. - Laboratorios Del Dr. Esteve S.A. - Shire Plc - Synageva BioPharma Corp. - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/jf...saccharido
GEVA: 238.60 (+2.80), BMRN: 89.65 (-1.84), SHPG: 187.47 (-0.74)
5 Healthy Stocks in the Top Biotech ETF - ETF News And Commentary
Sweta Killa - ZACKS - Wed Jun 17, 2:30AM CDT
We have highlighted the five best performing stocks in the top biotech ETF that more than doubled so far this year.
SBIO: 23.85 (+0.23), HALO: 9.17 (+0.06), GEVA: 238.60 (+2.80), IMGN: 3.08 (-0.12), HZNP: 19.15 (+0.44), ANAC: 99.06 (-0.14)
Lysosomal Storage Disorder Pipeline Review, H1 2015 - 15 Companies & 27 Drug Profiles
M2 - Thu Jun 11, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxz52s/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - BBB Therapeutics B.V. - Chiesi Farmaceutici SpA - Fate Therapeutics, Inc. - Minoryx Therapeutics s.l. - Neuralstem, Inc. - Nuo Therapeutics, Inc. - Orphazyme ApS - Oxyrane Belgium NV - REGiMMUNE Corporation - Sagetis Biotech, S.L. - Sangamo BioSciences, Inc. - Synageva BioPharma Corp. - Ultragenyx Pharmaceutical Inc. Drug Profiles - 2B3-201 - ALD-601 - Chaperone-ERT Combinations - Delta-tocopherol - FT-1050 - ML-SA1 - NSI-566 - Orph-001 - Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Recombinant Enzyme for LSD-2 Disease - Recombinant Enzyme for LSD-3 Disease - Recombinant Enzyme for LSD-4 Disease - Recombinant Enzyme for LSD-5 Disease - Recombinant Enzyme for Lysosomal Storage Disorder - Recombinant Enzyme to Activate LRP1 for Lysosomal Storage Disorder - RGI-5000 - SAG-002 - SBLSD-3 - SBLSD-4 - sebelipase alfa - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecules for GM1-gangliosidosis And Morquio B - Small Molecules for Lysosomal Storage Disorders - Stem Cell Therapy for Lysosomal Storage Disorder - UX-002 - UX-004 - ZA-011 For more information visit http://www.researchandmarkets.com/research/vx...al_storage
FATE: 1.73 (-0.04), GEVA: 238.60 (+2.80), SGMO: 6.09 (-0.09), FOLD: 6.00 (unch), CUR: 0.29 (unch)
Synageva BioPharma Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB
PR Newswire - Thu Jun 04, 3:05PM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the completion of enrollment in a Phase 1/2 trial with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome).
GEVA: 238.60 (+2.80)
Fabry Disease Pipeline Review, H1 2015 Edition
M2 - Thu Jun 04, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9l8prv/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - Synageva BioPharma Corp. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Alpha-Galactosidase - Genz-682452 - GZ-402671 - JR-051 - migalastat hydrochloride - Next Generation biologics for Pompe, Fabry and Hunter - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease For more information visit http://www.researchandmarkets.com/research/9l...ry_disease
GEVA: 238.60 (+2.80), IBIO: 0.69 (+0.01), FOLD: 6.00 (unch)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Synageva BioPharma Corp.
BusinessWire - Tue Jun 02, 6:29PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp. ("Synageva" or "the Company"
(Nasdaq: GEVA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion" . GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
Alexion satisfies Hart-Scott-Rodino waiting period for proposed acquisition of Synageva
M2 - Mon Jun 01, 3:24AM CDT
Biopharmaceutical company Alexion Pharmaceuticals (Nasdaq:ALXN) said on Friday that it has met the US Federal Trade Commission's (FTC) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to its planned acquisition of Synageva BioPharma (Nasdaq:GEVA).
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion's Pending Acquisition of Synageva
BusinessWire - Fri May 29, 3:20PM CDT
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) and Synageva BioPharma Corp. (Nasdaq:GEVA) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Alexion's pending acquisition of Synageva. The waiting period was scheduled to expire on June 15, 2015.
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
Synageva BioPharma Files for Kanuma's Approval in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 27, 11:30AM CDT
Synageva BioPharma Corp. (GEVA) submitted its New Drug Application (NDA) for Kanuma (sebelipase alfa) in Japan for the treatment for patients suffering from lysosomal acid lipase deficiency.
VRX: 23.29 (+0.04), GEVA: 238.60 (+2.80), GILD: 86.85 (+0.30), ALXN: 125.47 (+1.05)
Synageva BioPharma Submits Kanuma(TM) (Sebelipase Alfa) Application For LAL Deficiency In Japan
PR Newswire - Tue May 26, 3:05PM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kanuma(TM) (sebelipase alfa) as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency). Upon approval, Kanuma would be the first approved therapy for these patients.
GEVA: 238.60 (+2.80)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Synageva BioPharma Corp. -GEVA
PR Newswire - Fri May 22, 10:26AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp. ("Synageva" or "the Company"
(Nasdaq -GEVA-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion" . GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Synageva BioPharma Corp. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Alexion Pharmaceuticals, Inc. -- GEVA
PR Newswire - Mon May 18, 3:10PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
SYNAGEVA BIOPHARMA CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Synageva BioPharma Corp. Over the Proposed Sale of the Company to Alexion Pharmaceuticals, Inc.
BusinessWire - Mon May 18, 1:28PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synageva BioPharma, Inc. ("Synageva" or the "Company"
(Nasdaq: GEVA) for potential breaches of fiduciary duties in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion" (Nasdaq: ALXN) for approximately $8.4 billion in a cash and stock transaction. The deal gives Synageva shares a total value of $226; $115 of which will be paid in cash, while the remaining $111 will be paid for in Alexion stock. GEVA: 238.60 (+2.80), ALXN: 125.47 (+1.05)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synageva BioPharma Corp. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Wed May 13, 3:37PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synageva BioPharma Corp. ("Synageva" or the "Company"
(Nasdaq: GEVA) relating to the proposed buyout of the Company by Alexion Pharmaceuticals, Inc. GEVA: 238.60 (+2.80)
